News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 25–36 of 243 stories

Sable Bio and Instem Partner to Integrate AI Target Intelligence into KnowledgeScan

Sable Bio has partnered with Instem to integrate its Target Intelligence technology into KnowledgeScan, Instem's target safety assessment platform. The cloud-based service combines AI-supported scientific literature analysis with optional review by Instem's safety specialists, helping drug discovery teams identify potential safety risks earlier in target evaluation.

T-Cypher Bio Relocates to Purpose-Built Laboratories at Abingdon Science Park

T-Cypher Bio has announced its relocation to purpose-built laboratory and office space at Barton House, Abingdon Science Park, developed by Kadans Science Partner. The new premises will support the Oxford biotechnology company's T-cell receptor-based T-cell engager programmes for solid tumours and autoimmune diseases as they advance through preclinical development.

Mogrify to Present Preclinical Retinal Reprogramming Data at FLORetina 2026

Cambridge-based Mogrify has announced plans to present preclinical proof-of-concept data for its in vivo retinal reprogramming programme at the FLORetina-ICOOR congress in December 2026. The company reports that transcription factor combinations preserved and restored aspects of visual function in a rodent model of photoreceptor degeneration; the programme remains preclinical and Mogrify is seeking development partners.

Ori Biotech and Europlaz Expand Manufacturing Partnership for IRO Cell Therapy Consumables

Ori Biotech has announced an expanded strategic manufacturing partnership with UK contract manufacturer Europlaz to support reliable supply of its GMP-ready IRO cell therapy consumables. Building on work together since 2023, the arrangement provides for dedicated cleanroom space, equipment access and inventory management as cell therapy developers move towards commercial-scale manufacturing; it is not an announcement of a new regulatory approval.

Yourgene Health's Insight DPYD Assay Gains Australian Regulatory Approval

Novacyt has announced Australian Therapeutic Goods Administration approval for the Yourgene Insight DPYD assay, manufactured by its Yourgene Health business, for clinical diagnostic use. The pharmacogenetic test detects 19 DPYD variants associated with elevated risk of severe toxicity from 5-fluorouracil chemotherapy; Novacyt subsidiary Southern Cross Diagnostics holds the Australian registration and can supply the assay in that market.

CPI and Labman Demonstrate Autonomous Bioreactor Control for HER2 Antibody Production

A Canada-UK collaboration involving CPI, Labman, Basetwo AI and Nicoya has demonstrated autonomous, AI-driven bioreactor control during production of a trastuzumab biosimilar candidate targeting HER2-positive breast cancer. The project combined automated sampling, bioprocess analytics and predictive control to adjust nutrient feeding, maintaining process conditions and demonstrating a potential route to more efficient biologics manufacturing.

Lab Thread Launches Laboratory AI Tools and MCP Server, Opens Boston Office

UK laboratory software company Lab Thread has launched a Model Context Protocol (MCP) server enabling authorised external AI assistants to query structured laboratory data, alongside AI tools for protocol creation, notebook entry and equipment setup. The announcement also confirms US incorporation and the opening of a Boston office to support its growing customer base in the United States.

Levicept Presents Additional Phase 2 LEVI-04 Osteoarthritis Analyses at ACR 2026

Levicept has presented further analyses from its previously reported 518-patient Phase 2 trial of LEVI-04, an investigational non-opioid treatment for osteoarthritis, at ACR Convergence 2026. Ex vivo testing of patient samples supported selective inhibition of neurotrophin-3 without blocking nerve growth factor activity, while post-hoc analyses examined patient-reported pain and function; these are additional analyses, not results from a new trial.

Funding & Grants10 Nov 2026

Neobe Therapeutics Raises $6.8m Seed Round for Engineered Bacteria Cancer Therapies

Stevenage-based Neobe Therapeutics has raised $6.8m (£5m) in seed financing led by ARC Ventures, with participation from Macmillan Ventures, Proven Connect, Empirical Ventures, Faber and existing investor 2048 Ventures. The company is developing engineered bacteria intended to break down barriers surrounding solid tumours, with the aim of improving access for cancer drugs and immune cells.

Funding & Grants10 Nov 2026

Oyster Therapeutics Raises $60m Series A-2 and Rebrands from Kesmalea

London-based Kesmalea Therapeutics has rebranded as Oyster Therapeutics and closed a $60m Series A-2 financing led by 4BIO Capital. New investors include Eli Lilly, CE Ventures, Actium Group and TOHO Ventures, alongside existing backers including Syncona and Oxford Science Enterprises. The funding will advance Oyster's oral, brain-penetrant tau degrader towards clinical development for Alzheimer's disease and other tauopathies, and support its SELFTAC targeted protein degradation platform.